FY2027 EPS Estimates for Transcat Reduced by HC Wainwright

Key Points

• HC Wainwright has revised its FY2027 earnings estimate for Transcat, Inc. to $2.45 per share, down from $2.58, while maintaining a "Buy" rating with a target price of $116.00.
• The consensus estimate for Transcat's current full-year earnings stands at $2.30, with a current market price of $90.43.
• Institutional investors hold a significant majority of Transcat's stock, owning 98.34% of the company, with several acquiring new positions recently.

Transcat, Inc. (NASDAQ:TRNS - Free Report) - Research analysts at HC Wainwright decreased their FY2027 earnings estimates for Transcat in a research report issued on Friday, August 22nd. HC Wainwright analyst S. Buck now forecasts that the scientific and technical instruments company will post earnings of $2.45 per share for the year, down from their prior forecast of $2.58. HC Wainwright currently has a "Buy" rating and a $116.00 target price on the stock. The consensus estimate for Transcat's current full-year earnings is $2.30 per share.

Several other equities research analysts have also commented on the stock. Lake Street Capital initiated coverage on shares of Transcat in a report on Thursday, July 10th. They issued a "buy" rating and a $105.00 price target on the stock. Wall Street Zen raised shares of Transcat from a "sell" rating to a "hold" rating in a report on Wednesday, May 28th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $112.20.

Transcat Price Performance

NASDAQ:TRNS opened at $90.43 on Monday. Transcat has a one year low of $67.56 and a one year high of $133.72. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.36 and a current ratio of 2.92. The firm has a market cap of $842.81 million, a price-to-earnings ratio of 63.24 and a beta of 0.71. The firm's fifty day moving average is $82.82 and its two-hundred day moving average is $80.69.

Transcat (NASDAQ:TRNS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The scientific and technical instruments company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.40 by $0.19. Transcat had a net margin of 4.64% and a return on equity of 6.66%. The company had revenue of $76.42 million for the quarter, compared to analyst estimates of $72.28 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Lazard Asset Management LLC acquired a new position in shares of Transcat in the second quarter worth about $54,000. Quantbot Technologies LP acquired a new position in shares of Transcat in the first quarter worth about $76,000. Parkside Financial Bank & Trust acquired a new position in shares of Transcat during the 2nd quarter worth about $79,000. PNC Financial Services Group Inc. raised its position in shares of Transcat by 1,118.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,072 shares of the scientific and technical instruments company's stock worth $92,000 after purchasing an additional 984 shares during the last quarter. Finally, State of Wyoming acquired a new position in shares of Transcat during the 1st quarter worth about $95,000. Institutional investors and hedge funds own 98.34% of the company's stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.